Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-225-0096
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.84 million
Profitability
Miscellaneous
Employees48
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions
What is Proteostasis Therapeutics' stock symbol?
Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."
How were Proteostasis Therapeutics' earnings last quarter?
Proteostasis Therapeutics Inc (NASDAQ:PTI) issued its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.39) by $0.11. The business earned $5 million during the quarter, compared to analyst estimates of $0.80 million. Proteostasis Therapeutics had a negative return on equity of 84.01% and a negative net margin of 1,307.84%. View Proteostasis Therapeutics' Earnings History.
When is Proteostasis Therapeutics' next earnings date?
What price target have analysts set for PTI?
4 brokers have issued 12 month target prices for Proteostasis Therapeutics' shares. Their predictions range from $5.00 to $15.00. On average, they anticipate Proteostasis Therapeutics' share price to reach $11.3333 in the next twelve months. This suggests a possible upside of 989.7% from the stock's current price. View Analyst Price Targets for Proteostasis Therapeutics.
What is the consensus analysts' recommendation for Proteostasis Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Proteostasis Therapeutics.
What are Wall Street analysts saying about Proteostasis Therapeutics stock?
Here are some recent quotes from research analysts about Proteostasis Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and are lowering out 12-month PT to $14 from $21 on Proteostasis (due to lowering the probability of success on the program from 55% to 40%). This morning, the company announced and hosted a conference call to provide results from the low- and high-dose data from the triplet (PTI-801/808/428) trial. Additionally, the company announced data from the combination studies of on top of SYMDEKO. We feel the results were inferior to our projections, but believe data by year-end 2019 could make the case whether PTI’s internal drugs could be a competitive entrant in cystic fibrosis (CF)." (3/25/2019)
- 2. According to Zacks Investment Research, "Proteostasis Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network primarily in the United States. Proteostasis Therapeutics, Inc. is based in Cambridge, Massachusetts. " (3/15/2019)
Has Proteostasis Therapeutics been receiving favorable news coverage?
News coverage about PTI stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Proteostasis Therapeutics earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Proteostasis Therapeutics.
Who are some of Proteostasis Therapeutics' key competitors?
Some companies that are related to Proteostasis Therapeutics include Avid Bioservices (CDMO), MannKind (MNKD), Cerecor (CERC), Affimed (AFMD), Marinus Pharmaceuticals (MRNS), Bicycle Therapeutics (BCYC), Aldeyra Therapeutics (ALDX), Mersana Therapeutics (MRSN), Poxel (PXXLF), Kala Pharmaceuticals (KALA), Ocular Therapeutix (OCUL), Aeglea Bio Therapeutics (AGLE), Aclaris Therapeutics (ACRS), IDEAYA Biosciences (IDYA) and Galectin Therapeutics (GALT).
What other stocks do shareholders of Proteostasis Therapeutics own?
Who are Proteostasis Therapeutics' key executives?
Proteostasis Therapeutics' management team includes the folowing people:
- Ms. Meenu Chhabra, Pres, CEO & Director (Age 47)
- Dr. Benito Munoz, Chief Scientific Officer (Age 57)
- Dr. Po-Shun Lee, Exec. VP & Chief Medical Officer (Age 50)
- Ms. Sandra Zimmerman, VP of Fin., Principal Financial Officer & Principal Accounting Officer
- Ms. Sheila Gilbride Wilson, Chief Operating Officer
When did Proteostasis Therapeutics IPO?
(PTI) raised $51 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.
Who are Proteostasis Therapeutics' major shareholders?
Proteostasis Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (0.45%), Bailard Inc. (0.23%), Algert Global LLC (0.13%), Hikari Power Ltd (0.10%) and Virtu Financial LLC (0.04%). Company insiders that own Proteostasis Therapeutics stock include Cormorant Asset Management, Ll, Enterprise Associates 12 New, Franklin M Berger, Meenu Chhabra and Po Shun Lee. View Institutional Ownership Trends for Proteostasis Therapeutics.
Which major investors are selling Proteostasis Therapeutics stock?
Which major investors are buying Proteostasis Therapeutics stock?
PTI stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Algert Global LLC, Hikari Power Ltd and Virtu Financial LLC. Company insiders that have bought Proteostasis Therapeutics stock in the last two years include Enterprise Associates 12 New, Franklin M Berger and Meenu Chhabra. View Insider Buying and Selling for Proteostasis Therapeutics.
How do I buy shares of Proteostasis Therapeutics?
Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Proteostasis Therapeutics' stock price today?
One share of PTI stock can currently be purchased for approximately $1.04.
How big of a company is Proteostasis Therapeutics?
Proteostasis Therapeutics has a market capitalization of $53.14 million and generates $2.84 million in revenue each year. The company earns $-61,830,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. Proteostasis Therapeutics employs 48 workers across the globe.View Additional Information About Proteostasis Therapeutics.
What is Proteostasis Therapeutics' official website?
How can I contact Proteostasis Therapeutics?
Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]
MarketBeat Community Rating for Proteostasis Therapeutics (NASDAQ PTI)
| Community Ranking: | | 2.4 out of 5 ( ) |
| Outperform Votes: | | 237 (Thanks for Voting!) |
| Underperform Votes: | | 265 (Thanks for Voting!) |
| Total Votes: | | 502 |
